Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis

Enver Akalin, Vinita Sehgal, Scott Ames, Sabera Hossain, Lisa Daly, Murphy Barbara, Jonathan S. Bromberg

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The clinical patterns and predictors of cytomegalo-virus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14% (4% tissue-invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient- CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment.

Original languageEnglish (US)
Pages (from-to)731-735
Number of pages5
JournalAmerican Journal of Transplantation
Volume3
Issue number6
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus
Virus Diseases
Viruses
Transplants
Incidence
Pancreas
Tissue Donors
Kidney
valganciclovir
Transplant Recipients
Therapeutics

Keywords

  • Cytomegalovirus
  • Ganciclovir
  • Thymoglobulin
  • Transplantation
  • Valganciclovir

ASJC Scopus subject areas

  • Immunology

Cite this

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. / Akalin, Enver; Sehgal, Vinita; Ames, Scott; Hossain, Sabera; Daly, Lisa; Barbara, Murphy; Bromberg, Jonathan S.

In: American Journal of Transplantation, Vol. 3, No. 6, 06.2003, p. 731-735.

Research output: Contribution to journalArticle

Akalin, Enver ; Sehgal, Vinita ; Ames, Scott ; Hossain, Sabera ; Daly, Lisa ; Barbara, Murphy ; Bromberg, Jonathan S. / Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. In: American Journal of Transplantation. 2003 ; Vol. 3, No. 6. pp. 731-735.
@article{8c1c7a4edd5d4bd297c32ba8c72cb0e4,
title = "Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis",
abstract = "The clinical patterns and predictors of cytomegalo-virus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14{\%} (4{\%} tissue-invasive, 10{\%} noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient- CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17{\%}, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment.",
keywords = "Cytomegalovirus, Ganciclovir, Thymoglobulin, Transplantation, Valganciclovir",
author = "Enver Akalin and Vinita Sehgal and Scott Ames and Sabera Hossain and Lisa Daly and Murphy Barbara and Bromberg, {Jonathan S.}",
year = "2003",
month = "6",
doi = "10.1034/j.1600-6143.2003.00140.x",
language = "English (US)",
volume = "3",
pages = "731--735",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis

AU - Akalin, Enver

AU - Sehgal, Vinita

AU - Ames, Scott

AU - Hossain, Sabera

AU - Daly, Lisa

AU - Barbara, Murphy

AU - Bromberg, Jonathan S.

PY - 2003/6

Y1 - 2003/6

N2 - The clinical patterns and predictors of cytomegalo-virus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14% (4% tissue-invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient- CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment.

AB - The clinical patterns and predictors of cytomegalo-virus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14% (4% tissue-invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient- CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment.

KW - Cytomegalovirus

KW - Ganciclovir

KW - Thymoglobulin

KW - Transplantation

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=0037531594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037531594&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2003.00140.x

DO - 10.1034/j.1600-6143.2003.00140.x

M3 - Article

C2 - 12780565

AN - SCOPUS:0037531594

VL - 3

SP - 731

EP - 735

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -